(2S)-5-amino-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-N-[4-(methoxymethyl)phenyl]pentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-5-amino-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-N-[4-(methoxymethyl)phenyl]pentanamide
• 化学式: C₁₈H₃₀N₄O₃
• 分子量: 350.5
• InChiKey: PRDLBOXDTKQCBE-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• BIFUNCTIONAL CYTOTOXIC AGENTS
  申请人：Pfizer Inc.

  公开号：US20150209445A1

  公开（公告）日：2015-07-30

  Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

  细胞毒性二聚体包括基于CBI和/或CPI的亚单位，包括这种二聚体的抗体药物结合物，以及使用它们治疗癌症和其他疾病的方法。
• [EN] HYDROXY-POLMER-DRUG-PROTEIN CONJUGATES<br/>[FR] CONJUGUÉS HYDROXY-POLYMÈRE-MÉDICAMENT-PROTÉINE
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093640A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric scaffold having one or more -LD-D, the PBRM being connected to the polymeric scaffold by Lp, wherein the polymeric scaffold comprises a linear, branched or cyclic polymer having four or more -OH groups. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric scaffold respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.